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Abstract
Background: It has been previously demonstrated in several cancer models, that Dronabinol (THC) may have
anti-tumor activity – however, controversial data exists for acute leukemia. We have anecdotal evidence that THC
may have contributed to disease control in a patient with acute undifferentiated leukemia.
Methods: To test this hypothesis, we evaluated the antileukemic efficacy of THC in several leukemia cell lines and
native leukemia blasts cultured ex vivo. Expression analysis for the CB1/2 receptors was performed by Western
immunoblotting and flow cytometry. CB-receptor antagonists as well as a CRISPR double nickase knockdown
approach were used to evaluate for receptor specificity of the observed proapoptotic effects.
Results: Meaningful antiproliferative as well as proapoptotic effects were demonstrated in a subset of cases – with
a preference of leukemia cells from the lymphatic lineage or acute myeloid leukemia cells expressing lymphatic
markers. Induction of apoptosis was mediated via CB1 as well as CB2, and expression of CB receptors was a
prerequisite for therapy response in our models. Importantly, we demonstrate that antileukemic concentrations are
achievable in vivo.
Conclusion: Our study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in
a well defined subset of acute leukemia patients.
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Background
Delta9-Tetrahydrocannabinol is the major psychoactive
constituent of Cannabis sativa and signals through G-
protein-coupled cannabinoid receptors (CB).
The CB1 receptor is predominantly abundant in brain
tissues [1]. In contrast, the CB2 receptor was initially de-
scribed in the lymphatic system [2], but is also expressed
in other tissues such as brain [3], brain endothelium [4],
bone [5] or skin [6].
While the central CB1 receptor accounts for the psycho-
tropic, analgetic, and orectic effects, the dominantly periph-
eral CB2 receptor is linked to immunomodulation [7] and
regulation of bone mass [5] among other functions.
Despite the broadly acknowledged potential of canna-
binoid agonists with regard to effective relief of tumor or
neuropathic pain, muscular spasm or nausea—combined
with an excellent safety profile and moderate side-
effects—clinical use is very restricted in most countries
due to the unwanted psychoactive effects (reviewed by
Pertwee [8]). The natural (−)-Δ9-Tetrahydrocannabinol
isomer dronabinol (further referred to as THC) is a potent
pan-cannabinoid receptor (CB1/2) agonist, which gained
FDA-approval in the United States as Marinol® for the
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treatment of chemotherapy-induced nausea and vomiting
or stimulation of appetite in AIDS patients.
Moreover and importantly, there is evidence for
growth-inhibiting effects in tumor models, including ani-
mal models, arguing for the use of cannabinoids as low-
toxic anticancer therapeutics (reviewed by Guzman [9]).
Anecdotal evidence has lead us to speculate that THC
may have contributed to disease control in a patient with
acute undifferentiated leukemia. Indeed, previous reports
suggest a proapoptotic antitumor effect of CB-agonists on
acute leukemia cells in vitro [10–12]. These studies con-
centrate on the analysis of the Jurkat T-lymphoblastic cell
line (which was established from the peripheral blood of a
patient suffering from acute T-lymphoblastic leukemia in
1976; see also http//:https://www.dsmz.de). However, the
mechanism of action is controversially discussed in these
studies (CB1 versus CB2 mediation) [11, 12].
Even more controversially, other studies suggest a
hematopoietic growth advantage mediated via CB2 activa-
tion – and utmost challenging, characterize CB2 as an
oncoprotein linked to (myeloid) leukemogenesis [13–15].
We now provide data demonstrating potent antileuke-
mic efficacy of THC in acute leukemia cell lines in vitro
as well as freshly harvested native leukemia blasts cul-
tured ex vivo. Notably, antiproliferative as well as proa-
poptotic effects are preferentially seen in leukemia cells
of the lymphatic lineage or in acute myeloid leukemia
cells expressing lymphatic markers.
Results
THC inhibits cellular proliferation in lymphatic and
myeloid leukemia cell lines
In analogy to previous reports, we used the T-
lymphoblastic leukemia cell line Jurkat to reconfirm
whether THC is capable to inhibit cellular prolifera-
tion in an acute leukemia cell model. THC was ad-
ministered for 72 h in a dose dependent manner and
the antiproliferative effect, measured as the reduction
of XTT metabolism in correlation to an untreated nega-
tive control, was measured accordingly. THC produced
significant and dose-dependent inhibition of cellular pro-
liferation (Fig. 1a) with a computed IC50 ~ 15 μM in a
non-linear regression analysis (Fig. 1b).
To determine, whether the observed effects are unique
to the Jurkat cell line, we also tested an acute myeloid
leukemia cell line, MOLM13 – and found similar anti-
proliferative effects with an IC50 ~ 18 μM (Fig. 1c, d).
At the higher tested doses >50 μM, virtual no meta-
bolic activity was observed for both Jurkat as well as
MOLM13 cells – arguing that cells are not viable and
may have been directed to programmed cell death. In
this context, it has been previously described, that can-
nabinoid agonists are capable to induce apoptosis in
tumor cells [16].
THC induces apoptosis in leukemia cell lines
We addressed this question in an annexin V-based flow
cytometry assay and treated Jurkat as well as MOLM13
cells with increasing concentrations of THC for 48 h.
For Jurkats, we were able to demonstrate dose-
dependent induction of apoptosis with significant p values
starting at 40 μM in a Student’s t-test (Fig. 2a). IC50 was
computed in a non-linear regression analysis at ~46 μΜ
(Fig. 2b). No signs of cell cycle arrest with abrogation of
the proapoptotic effect in higher doses [17] were seen: At
the highest tested dose, 75 μM, a virtual complete kill of
the entire population was observed (Fig. 2c).
Additional annexin V-staining data is provided in
Additional file 1: Figure S1, demonstrating dose-dependent
induction of early apoptosis in Jurkat cells treated with
THC for 10 h.
It has been previously demonstrated for Jurkat leukemia
cells, that THC-mediated induction of apoptosis is linked
to the intrinsic, mitochondrial pathway [10]. We con-
firmed this finding in Western immunoblots showing
cleavage of caspases 3 and 9 upon treatment with THC
(Fig. 5c and Additional file 2: Figure S2). Cleaved caspase
9 is known as a central mediator of the intrinsic mito-
chondrial apoptosis pathway.
Similarly, MOLM13 cells underwent induction of
apoptosis in response to THC with a computed IC50 ~
38 μM and complete kill of cells at 75 μM (Fig. 2d–f ).
A drug-carrier (i.e. methanol) control assay did not re-
veal any significant proapoptotic effects at the highest
concentration used with the THC-dilution experiments.
To diminish individual cell line-specific effects, we ex-
panded our analysis to other leukemia cell line models.
For our experiments, we used MOLM14 cells, a sister
cell line of MOLM13 derived from the same patient, as
well as independent acute myeloid leukemia cell lines
(MV4-11, M0-7e, HL60), the core binding factor cell line
Kasumi1 and the acute blast crisis CML cell line K562.
All cell lines were treated with THC in a dose
dependent manner and induction of apoptosis was mea-
sured after 24 and 48 h.
Together, THC was capable of inducing apoptosis in
all leukemia cell lines—whereas IC50s differed in between
the tested cell lines. A summary of computed IC50s is
provided with Table 1. Dose-effect plots and dose-
regression analysis for each cell line are provided as sup-
plemental data (Additional file 3: Figure S3, Additional
file 4: Figure S4, Additional file 5: Figure S5, Additional
file 6: Figure S6, Additional file 7: Figure S7, Additional
file 8: Figure S8).
THC reduces the proportion of viable cells cultured
ex vivo
We next tested native leukemia blasts cultured ex vivo,
with regard to the antileukemic sensitivity after exposure
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to THC with doses in the range of IC50s for the Jurkat
cell line.
As a relatively high basal proportion of dead/apoptotic
cells was present in the freshly harvested and cultured
cells, which is a commonly observed problem in ex vivo
cell cultures, we used a flow cytometry-based assay as
recently established by our group (Kampa-Schittenhelm
et al. [18]) measuring reduction of the viable cell propor-
tion in a FSC/SSC scatter plot. To ensure that the gated
population is viable an annexin V/PI-based assay was
performed simultaneously using THC-naïve cells. The
viable cell fraction was defined as absence of annexin V
or PI positivity and the gate was set accordingly. Further,
immunophenotyping was set up to confirm the leukemic
character of the gated population (i.e. CD45low+/-CD34
positivity). Reduction of the viable cell fraction was mea-
sured 48 h after THC exposure compared to treatment-
naive parental cells. Density dot plots of a representative
patient sample are provided in Fig. 3a–e.
Dose-effect waterfall bar graphs demonstrating reduction
of viable cells in lymphatic as well as myeloid leukemia pa-
tient samples are provided with Fig. 3f (myeloid leukemia)
and Fig. 3g (lymphatic leukemia). In general, leukemias
with lymphatic differentiation were more sensitive to
THC—with 9/13 (69 %) patients showing an at least ~50 %
reduction of viable cells at 50 μM. In contrast, only 4/13
(31 %) patients with AML demonstrated a ≥50 % reduction
of the viable cell proportion.
Response to THC correlates with expression of CB1 and
CB2 receptors
To evaluate, whether response to THC correlates with can-
nabinoid receptor expression, we measured protein expres-
sion levels of CB1 and CB2 on all available patient samples
Fig. 1 Photometric XTT-analysis assaying metabolic active cells in dependence of THC concentration. Representative dose-effect curves for Jurkat
(a) and MOLM13 (c) cells treated with THC in a dose-dependent manner are shown on. Student’s t-test analysis reveals significant reduction of
proliferating cells as indicated for two doses (statistical significance at p < 0.05). Experiments were performed in triplicates. Linear regression
analysis was performed to compute IC50s for both cell lines (b and d)
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Fig. 2 (See legend on next page.)
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using a flow cytometry-based assay. Antibody-specificity
was validated by Western immunoblots and flow cytome-
try analysis using MOLM and Jurkat cell lines (Fig. 4a–b).
Marked CB1 as well as CB2 expression was confirmed
in 4/12 evaluated patients. Interestingly, expression of
CB1 as well as CB2 was individually but equally elevated
in these patients. The remaining 8 patients showed sig-
nificantly lower expression levels of either of the recep-
tors (Fig. 4c). Comparative evaluation of CB receptor
expression levels in 10 healthy bone marrow donors re-
vealed similar low expression levels.
Notably, correlation of CB-expression levels with re-
sponders to THC (defined as an apoptosis rate of at least 20 %
upon treatment with THC for 48 h) revealed that expression
of the cannabinoid receptors is a definite prerequisite to
achieve any proapoptotic effect in native leukemia blasts.
The proapoptotic effect of THC is mediated via CB1 – as
well as CB2
As both receptors were equally increased or diminished
in all tested cell lines and patient samples, we asked
whether the observed proapoptotic effect can be linked
to one specific receptor.
We established an assay to specifically block the CB1
or CB2 receptor prior to exposure of leukemia cells to
THC and used MOLM13 or Jurkat cells as a myeloid, re-
spective lymphoid leukemia model:
LY320135, a highly selective cannabinoid receptor an-
tagonist with a 70-fold higher affinity to CB1 than CB2
and a selective CB2 inverse ligand agonist (JTE-907)
were first tested in dose-dependent dilution series in
both cell lines to determine the optimal concentration
without an intrinsic cell toxic effect (Fig. 5a).
Jurkat or MOLM13 cells were next treated with sub-
toxic doses of either LY320135 or JTE-907 at 0,1 μg/ml
for 12 h. THC was then administered at ~ IC50 doses
and cells were incubated for an additional 48 h. Notably,
both inhibitors were able to abrogate THC-mediated in-
duction of apoptosis in Jurkat cells as well as the
MOLM13 cell line (Fig. 5b). As statistical analysis closely
failed significance for CB2-interfered cell strains, we set
up an alternative approach to confirm CB1- as well as
CB2-dependency of the proapoptotic effect in leukemia
cells: A knockout transfection approach was established
using a CRISPR double nickase plasmid selectively en-
coding for CB1 or CB2. Puromycin selection was used
to create stable CB1, resp. CB2 knockout cell strains of
the Jurkat leukemia cell line. Importantly, knockdown of
CB1 as well as CB2 resulted in highly significant abroga-
tion of proapoptotic effects upon treatment with THC
(see Additional file 9: Figure S9), supporting the finding
of a direct role of either of the cannabinoid receptors in
induction of apoptosis in acute leukemia models.
To confirm rescue from induction of apoptosis on the
protein level, cleavage of caspase 3 (as an indicator of ac-
tivated apoptosis signal transduction pathways) was de-
termined by western immunoblot experiments. Indeed,
THC-treated MOLM13 as well as Jurkat cells were
Table 1 Sensitivity of leukemia cell lines in response to THC
Patient No. Phenotype THC response
Entitiy lineage dependency is marked (+) aberrantly expressed antigens are separately indicated % viable
cells at 50 μM
IC50 (μM)
T-lymphatic B-lymphatic myeloid
K562 − − + 87 62
M07e − − + 81 59
HL60 CD4 − + 15 38
Kasumi1 CD4 − + 14 35
MV4-11 CD4 − + 3 39
MOLM14 CD4 − + 18 44
MOLM13 CD4 − + 3 33
Jurkat + − − 31 46
(See figure on previous page.)
Fig. 2 Flow cytometric apoptosis assay measuring early apoptotic (annexin V) and later phase apoptotic cells (propidium iodide) after exposure
of Jurkat (a-c) or MOLM13 (d-f) cells to THC. Dose-effect curves for Jurkat (a) and MOLM13 (d) cells treated with THC in a dose-dependent
manner are shown. Student’s t-test demonstrates significance (p < 0.05) of induction of apoptosis at 46 μM (Jurkat), resp. 32 μM (MOLM13).
Experiments were performed in triplicates. Non-linear regression analysis was performed to compute IC50s (b, e). Flow cytometry raw data are
shown for Jurkat (c) and MOLM13 (f) cells demonstrating overwhelming induction of apoptosis in the highest tested doses – with no effect for
methanol as drug carrier at the highest tested dose
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successfully rescued from caspase 3 cleavage after pre-
treatment of cells with LY320135 or JTE-907 (Fig. 5c).
Response to THC is higher in leukemia blasts expressing
lymphatic markers
As demonstrated in Fig. 3, responses to THC were pre-
dominantly seen in acute leukemia entities derived from
the lymphatic lineage. However, there was a subset of
myeloid leukemia patient samples that had considerable
sensitivity towards THC as well.
In an attempt, to further define the cohort responsive
towards THC, we performed a systematic review of all
available expression markers obtained at diagnosis—and
found that most sensitive AML samples aberrantly
expressed (T-) lymphoid differentiation markers
(Table 2).
In this context, it is utmost remarkable, that all ana-
lyzed leukemia cell lines with higher sensitivity towards
THC aberrantly express T-lymphatic antigens as well (sum-
marized in Table 1, see DSMZ homepage and Matsuo et al.
[19] for expression profiles of cell lines).
However, as ALL samples with sensitivity towards THC
were not restricted to the T-lineage, the observation of
linking T-cell markers with THC-response may be biased
due to the limited number of samples analyzed – and
AML cohorts expressing B-cell markers may respond to
THC as well. In our tested cohort, the only case express-
ing a B-differentiation marker (CD19, AML-6) did not
show significant sensitivity towards THC up to 50 μM.
Discussion
Treatment outcome for acute leukemia in adults is still
unsatisfactory for most entities. Besides disease-specific
limitations such as high-risk genomic or chromosomal
aberrations, comorbidities need to be addressed, espe-
cially in the increasing elderly population, restricting
Fig. 3 Reduction of the viable leukemia cohort upon treatment with THC. a FSC/SSC scatter plot was used to gate (R1) the viable cell population.
Counted cells (total) n = 30,000. b Viability of the R1-gated population was confirmed in an annexin V/PI-based apoptosis assay (viable population
located in the lower left (LL) section of a quadrant plot). c Immunophenotyping assay to distinguish the CD34 (PE conjugated) and/or CD45low
(FITC conjugated) positive leukemia population is shown. This cohort was followed prior to and 48 h after exposure to THC to determine reduction of
viable cells in response to THC (d and e). A representative patient sample is shown. Percental waterfall plots are provided for AML (f) and ALL (g) for all
tested patient samples
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therapeutic options to epigenetic approaches, symptom-
atic cytoreduction or best supportive care.
We here reveal a novel aspect of dronabinol, a cannabin-
oid derivative, which displays remarkable antiproliferative
as well as proapoptotic efficacy in a distinct leukemia pa-
tient cohort - in vitro and in ex vivo native leukemia blasts.
It has been previously reported that cannabinoids display
anticancer properties. However, due to legal issues the use
and exploration of such agents is highly limited in many
countries. Definition of dosing and entities benefitting
from these agents remain vague and despite mounting evi-
dence regarding their anti-tumorous effects cannabinoids
have not been further developed as anticancer agents.
Even more challenging, controversial data suggest that
cannabinoid agonists may foster tumorigenesis in some
entities: For an acute myeloid leukemia model it has
been demonstrated that CB2 has oncogene properties
abrogating myeloid differentiation [13, 20].
We now provide rigorous proof-of-principle data dem-
onstrating that (A) dronabinol has antiproliferative as
well as proapoptotic efficacy in a broad spectrum of
acute leukemia cell lines and native blasts cultured ex
vivo and (B) this effect was preferentially observed in
blasts with lymphoid differentiation or myeloid blasts
aberrantly expressing lymphatic antigens. (C) The proa-
poptotic effect of dronabinol is mediated via CB1 as well
as CB2 – and expression of the CB receptors is a pre-
requisite for therapy response. (D) Antitumor efficacy is
dose-dependent and achievable in vivo.
Despite numerous reports on the anti-cancerous effi-
cacy of THC the mechanisms of action as well as de-
fined responder populations still remain unclear. Our
data demonstrating antiproliferative as well as proapop-
totic efficacy in defined acute leukemia models as well as
ex vivo patient samples thereby aims to define a patient
sample cohort potentially profiting from dronabinol
Fig. 4 Expression of CB1 and CB2 in acute leukemia. a FACS flow cytometry based analysis of intracellular (CB1/2 perm) and extracellular CB
expression levels in MOLM and Jurkat cell lines. b Western immunoblotting expression analysis of CB1 and CB2 in Jurkat and MOLM leukemia cell
lines. The major isoform of CB1 (1a long) has a molecular weight of 52 KDa. CB2 is expected at 40-50 KDa. c Exracellular CB1/CB2 expression levels
of native leukemia cells (n = 12) and comparatively bone marrow donors (n = 10) and the Jurkat and MOM13 cell lines as assessed by flow cytometry.
The responder/nonresponder cohort (n = 4, resp. n = 8) contains patient samples responsive/non-responsive towards THC ex vivo. (*-****) statistical
significance at p < 0.05 (Student’s t-test)
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therapy. The observation that lymphoid blasts or mye-
loid samples expressing lymphatic markers are more
sensitive towards THC is extremely valuable for thera-
peutic decisions and the observed lineage-dependency
might explain the controversial results observed for can-
nabinoid activation in acute leukemia models in the past.
But studies on a larger patient cohort are necessary to
verify our observation and future studies will have to ad-
dress the underlying mechanisms.
The mediation via both cannabinoid receptors CB1 and
CB2 was verified using two different strategies – by transi-
ent silencing receptor activity via specific antagonists and
by CRISPR double nickase knockdown. Our in vitro data
is thereby backed up by the observation that all patient
samples sensitive towards THC presented with high pro-
tein expression levels of CB1 and CB2 receptors whereas
vice versa all non-responder displayed only low CB1/2 ex-
pression. We thus believe to shed new light into the iden-
tification of a potential responder cohort. Importantly, we
show that the healthy bone marrow donor population dis-
plays comparatively low CB1/2 expression as well. This is
important to assess and evaluate the necessary doses and
potential side effects.
Due to the excellent safety profile of dronabinol (com-
pare drug information of Marinol®) effective doses are
achievable in vivo. However, individual tolerable doses may
vary widely—and starting with a sub-effective dose to be
increased gradually may be necessary to build up tolerance
to the well known psychoactive effects.
In this context, we had the opportunity to extract
plasma from an elderly patient treated with dronabi-
nol under palliative supportive care considerations for
tumor kachexia. Dronabinol, provided by the univer-
sity hospital’s pharmacy as 2.5 % oily solution, was
started with 2 drops bid and tampered to 6 drops bid
without any side effects. The patient was not treated
with any antitumor or cytoreductive therapy. Plasma
was used to culture Jurkat cells—and a considerable
plasma inhibitory effect was documented in an apop-
tosis assay (Additional file 10: Figure S10). This ob-
servation argues for an antileukemic activity of
dronabinol in vivo.
Fig. 5 Proapoptotic effect of THC is mediated via CB1 and CB2. a The CB1 antagonist LY320135 and a selective CB2 inverse ligand agonist (JTE-907)
were tested in dose-dependent dilution series. Dose-effect plots from an apoptosis annexin V-based flow cytometry assay are shown. b MOLM13 and
Jurkat cells were pretreated with either antagonist (LY, LY320135; JTE, JTE-907) for 12 h and THC was administered for another 48 h (30 μM for Jurkat
and 45 μM for MOLM13 cells). Induction of apoptosis was analyzed as described above. (*-****) statistical significance at p < 0.05 (Student’s t-test).
c Western immunoblotting of cleaved caspase 3 in response to THC +/- preexposition to LY320135 or JTE-907 is shown.
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Due to sparse densities of cannabinoid receptors in lower
brainstem areas, which control cardiovascular and respira-
tory functions, severe intoxications with THC have rarely
been reported [21]. LC50s are not well defined (lethal con-
centration for male rats were 1270 mg/kg when orally ad-
ministered; compare http://toxnet.nlm.nih.gov) and dose-
limiting side effects may be due to cardiovascular effects by
lowering blood pressure and heart rate [22]. In this context
it is also important to mention that healthy tissues tend to
exhibit lower densities of cannabinoid receptors compared
to malignant tissues (see expression data described herein or
e.g. Kerner et al. who report on significantly higher CB2 ex-
pression in glioblastoma in comparison to healthy brain tis-
sue). These findings suggest that therapeutically relevant
and at the same time well tolerated proapoptotic doses can
be achieved in acute leukemias.
Importantly, our data is in line with findings of others
that have reported on the proapoptotic effect of cannabi-
noids in leukemia cell lines [22, 23]. Discrepancies for
IC50s of THC derivatives reported within different stud-
ies are likely due to the known instability and origin of
the compound, differences in the chosen time intervals
between treatment and analyses, and differing cell cul-
ture conditions, including FBS concentrations. In this
context, we have previously shown that FBS conditions
may have significant impact on in vitro sensitivity pro-
files of tumor cells towards chemo- or targeted thera-
peutics, linked to direct drug-protein interactions and
indirectly via effects on cell cycle regulation [17, 24].
Thus, our data provides a proof-of-principle, but effect-
ive clinical doses will need to be determined in vivo.
Cannabinoid receptor agonists as low-toxic agents may
be especially of interest in the context of heavily pre-
treated, elderly or therapy refractory disease. Notably, we
have evidence that dronabinol retained antileukemic
activity in a sample of an otherwise chemotherapy
and steroid-refractory ALL patient (see Additional
file 11: Figure S11).
Table 2 Sensitivity of native leukemia blasts in response to THC
Patient No. Phenotype THC response
Entity lineage dependency is marked (+)






sAML (MDS) N/A N/A + 100
AML-2
AML, FLT3-ITD − − + 100
AML-3
AML NOS (CD3) − + 100
AML−4
APL − − + 99
AML-5
AML, FLT3-ITD − − + 96
AML-6
AML, FLT3-ITD − CD19 + 91
AML-7
AML NOS (M0) − − + 89
AML-8
AML, FLT3-ITD − − + 88
AML-9
N/A N/A N/A + 69
AML-10 CD7
AML, FLT3-ITD CD56 − + 50
AML-11 CD7
sAML (MDS) CD5 − + 46
AML-12 (CD7)
AML NOS (M0) (CD5) − + 33
AML-13 CD7
CBF AML CD5 − + 20
ALL-1
(c) B-ALL − + − 97
ALL-2 CD33
pre B-ALL − + CD13 96
ALL-3
(c) B-ALL − + CD33 94
ALL-4
pre-B-ALL − + − 82
ALL-5
(c) B-ALL − + − 55
ALL-6
Cortical T-ALL + CD79 − 55
ALL-7
(c) B-ALL − + − 54
ALL-8 + CD33
Table 2 Sensitivity of native leukemia blasts in response to THC
(Continued)
pre B-ALL − CD10 CD13 53
ALL-9
(c) B-ALL − + − 48
ALL-10
(c) B-ALL − + − 43
ALL-11
Cortical T-ALL + − − 38
ALL-12 CD33
(c) B-ALL − + CD13 37
ALL-13 CD56
pre B-ALL CD1a + CD13 12
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In this context, a case report of a 14 year old girl
with refractory BCR-ABL1 (Ph+) ALL was recently
published demonstrating dramatic blast reduction in
an individual therapy approach using escalating doses
of a cannabis extract [25]. It is remarkable, that the
selected case fits into the defined responder cohort of
our study.
The compiled data demonstrates impressively, that
dronabinol should be considered in selected cases of
patients with acute leukemia but also stresses on the
importance of thoroughly reflecting on the individual
expression profiles of CB1/CB2 as well as on add-
itional diagnostic criteria—as e.g. lymphatic markers.
Even though it is not the intended purpose of this
article, it should not stay unmentioned that besides
the direct anti-leukemic effects of dronabinol the
therapeutical use of THC in this patient cohort might
exhibit a multitude of positive, desirable side effects
like general physical well-being, cachexia control as
well as pain, anxiety and stress relief, and thus should
facilitate the decision process.
Conclusion
To summarize, we provide a promising rationale for the
clinical use of cannabinoids, such as dronabinol, in dis-
tinct entities of acute leukemia—and this approach
should further be evaluated.
Methods
Cell lines
The CML blast crisis cell line K562, the MLL-AF9 fusion
positive acute myelogenous leukemia cell lines MOLM13
and the sister cell line MOLM14, both deriving from the
same patient [26], and the human hematopoietic growth
factor–dependent M-07e cell line were kindly provided by
Drs. Heinrich and Lopez, Oregon Health and Science
University, Portland, OR. The acute T-cell lymphoblastic
leukemia cell line Jurkat, the AML cell lines HL60 and
MV4-11 and the core binding factor leukemia cell line
Kasumi1 [27] were obtained from the German Collection
of Microorganisms and Cell Cultures (DSMZ).
Cells were cultured in RPMI 1640, supplemented with
10 % fetal bovine serum, 1 % penicillin G (10,000 units/
mL), and streptomycin (10,000 μg/mg) (GIBCO/Invitrogen,
Darmstadt, Germany or BiochromAG, Berlin, Germany).
Negativity for mycoplasma contamination was confirmed
using the pluripotent PCR Mycoplasma test kit (Appli-
Chem, Darmstadt, Germany). Cell lines harboring a mutant
KIT (Kasumi1), FLT3 (MOLM13; MOLM14, MV4-11) or
ABL (K562) isoform were sequence confirmed. M-07e
cells were cultured using 10 ng/ml recombinant hu-
man granulocyte-macrophage colony stimulating fac-
tor (GM-CSF) as a growth supplement.
Reagents
Dronabinol (i.e. (−)-Δ9-Tetrahydrocannabinol, THC),
dissolved in methanol, was obtained from THC Pharm
(Frankfurt/Main, Germany) with permission of the Federal
Opium Agency at the Federal Institute for Drugs and
Medical Device, Germany. The selective CB1 antagonist
LY320135 and the selective CB2 inverse agonist JTE-907
(CB2) were purchased from Sigma (St. Louis, MO).
Isolation of bone marrow and peripheral blood
mononuclear cells
Bone marrow aspirate and peripheral blood samples
from patients with diagnosed acute leukemia were col-
lected in 5000 U heparin after written informed consent,
including publication of the data, and approval of the
ethics committee of the University of Tübingen. Mono-
nuclear cells were isolated by Ficoll Hypaque density gra-
dient fractionation [17].
Immunoblotting
Cell pellets were lysed with 100 to 150 μL of protein
lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1 %
NP40, 0.25 % deoxycholate with added inhibitors aproti-
nin, AEBSF, leupeptin, pepstatin, sodium orthovanadate,
and sodium pyruvate, respectively phosphatase inhibitor
cocktails „2“and „1“or „3“(Sigma, St. Louis, MO). Protein
from cell lysates (75 to 200 μg protein) was used for
whole cell protein analysis after denaturing by Western
immunoblot assays using a BioRad Criterion system
(protein separation by SDS-PAGE in 3–8 % or 10 %
polyacrylamide gels followed by electroblotting onto
nitrocellulose membranes). Nonspecific binding was
blocked by incubating the blots in nonfat dry milk or
BSA. Primary antibodies were incubated for one hour or
over night, followed by several washes of Tris-buffered
saline (TBS) containing 0.005 % Tween 20. Goat anti-
human cannabinoid receptor 1 or 2 (CB1/CB2) anti-
bodies were purchased from Sigma (St. Louis, MO);
rabbit anti-human cleaved caspase 3 as well as 9 and
rabbit anti-mouse tubulin antibodies were obtained from
Cell Signaling Technology (Danvers, MA). The major
isoform of CB1 (1a long) has a molecular weight of 52
KDa. The molecular weight of CB2 is 39 KDa – and the
corresponding band in the immunoblot for the used
antibody is expected at 40-50 KDa according to the
manufacturer’s protocol. Donkey anti-goat/rabbit/mouse
infrared dye-conjugated secondary antibodies for the LI-
COR® imaging detection system were used according to
standard protocols (LI-COR Biosciences, Lincoln, NE).
Secondary antibodies were applicated for 30‘, followed
by several washes. Antibody-reactive proteins were de-
tected using a LI-COR Odyssey® fluorescence optical
system (LI-COR Biosciences, Lincoln, NE) [17].
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Apoptosis assays
Translocation of phosphatidylserine from the inner to the
outer leaflet of the plasma membrane as an early indicator
of apoptosis was analyzed using an annexin V-based assay
(Immunotech, Marseilles, France) and a FACScalibur®
flow cytometer loaded with CellQuest® analysis software
(BD, Heidelberg, Germany) [28].
Proliferation assays
Cellular proliferation capacity was measured using an
2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-
5-carboxanilide inner salt (XTT)–based assay (Sigma,
MO) [28].
Immunophenotyping
A routine panel for newly diagnosed acute leukemia was
performed for every patient following standard in-house
protocols. In addition, rabbit anti-human CB1 or CB2
antibodies (Cell Signaling Technology, Danvers, MA)
were conjugated with fluorescent polyclonal secondary
anti-rabbit IgG-H&L (FITC) antibodies (Cell Signaling
Technology as well) according to the manufacturer
protocol and protein expression levels were assessed by
flow cytometry using standard protocols.
Data analysis
Dose-effect plots were created to calculate IC50s using
Prism 5.0 Software available from Graph Pad, La Jolla, CA.
Additional files
Additional file 1: Figure S1. Induction of apoptosis determined by
externalization of phosphatidylserine. Jurkat cells are treated with THC for
10 h and analyzed using a flow cytometry annexinV staining protocol.
Histograms of representative experiments are provided. (TIFF 432 kb)
Additional file 2: Figure S2. Proapoptotic effect of THC is mediated via
the mitochondrial intrinsic pathway. Western immunoblotting of cleaved
caspase 9 in Jurkat cells treated with THC is shown. Tubulin serves as a
loading control. (TIFF 107 kb)
Additional file 3: Figure S3. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 557 kb)
Additional file 4: Figure S4. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 579 kb)
Additional file 5: Figure S5. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 567 kb)
Additional file 6: Figure S6. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 536 kb)
Additional file 7: Figure S7. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 527 kb)
Additional file 8: Figure S8. Flow cytometric apoptosis assay. Dose-effect
curves for leukemia cell lines treated with THC in a dose-dependent
manner are shown. Student’s t-test analysis demonstrates significance
(p < 0.05) of induction of apoptosis. Experiments were performed in tripli-
cates. Methanol as drug carrier was applicated at the highest tested dose
(left panels). Non-linear regression analysis was performed to compute IC50s
(right panels). (TIFF 563 kb)
Additional file 9: Figure S9. Plasma inhibitory efficacy. Plasma derived
from a patient supportively treated with dronabinol (6° bid of a 2.5 % oily
solution) for tumor kachexia in a palliative setting was extracted and used
to culture Jurkat leukemia cells for 48 and 72 h. Plasma inhibitory efficacy
was analyzed in an annexin V/PI-based apoptosis assay. (TIFF 1292 kb)
Additional file 10: Figure S10. Reduction of the viable leukemia
population upon treatment with THC. Immunphenotyping of the leukemic
clone in a FSC/SSC scatter plot was performed in a patient with refractory
ALL and >90 % blasts in the peripheral blood. Reduction of the population
was followed after exposure to THC for 48 h. Proportion of the remaining
viable cell proportion is shown in a dose-effect plot. (TIFF 282 kb)
Additional file 11: Figure S11. Sensitivity of Jurkat leukemia cells
towards THC after selective CB1-, resp. CB2, CRISPR knockdown. (A) Cells
are transfected using standard protocols of the manufacturer (Santa Cruz)
using a selective CB1, respectively CB2, CRISPR Double Nickase plasmid.
GFP transfection efficiency control by flow cytometry after puromycin
selection is shown. EV, empty vector negative control. (B) Validation of
CRISPR knockdown of CB1, resp. CB2 protein expression using a flow
cytometry approach. (C) Sensitivity of Jurkat cells towards THC (40 μM)
after selective CB1, resp. CB2, interference (CB1i/CB2i) with regard to
induction of apoptosis. Mean data of 3-5 independent annexin V/PI-
based experiments are provided. (*-**) statistical significance at
p < 0.05 (Student’s t-test). EV, empty vector. (TIFF 237 kb)
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